Ero sivun ”Rituksimabi” versioiden välillä
| [katsottu versio] | [katsottu versio] |
→Lähteet: ==Historiaa== |
p MiPe siirsi sivun Rituximab uudelle nimelle Rituksimabi: Suomeksi näin |
(ei mitään eroa)
| |
Versio 19. syyskuuta 2012 kello 15.34
Rituximab (MabThera ja Rituxan) on kimeerinen monoklonaalinen vasta-aine lääke potilaille jotka ovat CD20-positiivisia. Rituximab tuhoaa B-soluja ja siksi käytetään hoidettaessa sairauksia joissa esiintyy poikkeavan runsaasti B-soluja, yliaktiivisia B-soluja tai toimintahäiriöisiä B-soluja. Näitä ovat monet Lymfooma, leukemia, elinsiirtojen hylkimis reaktiot ja muutamat autoimmuunisairaudet.
Historiaa
Rituximab was developed by IDEC Pharmaceuticals under the name IDEC-C2B8.[1]
Based on its safety and effectiveness in clinical trials,[2] rituximab was approved by the U.S. Food and Drug Administration in 1997 to treat B-cell non-Hodgkin lymphomas resistant to other chemotherapy regimens.[3] Rituximab, in combination with CHOP chemotherapy, is superior to CHOP alone in the treatment of diffuse large B-cell lymphoma and many other B-cell lymphomas.[4] In 2010 it was approved by the European Commission for maintenance treatment after initial treatment of follicular lymphoma.[5]
Rituximab is currently co-marketed by Biogen Idec and Genentech in the U.S., by Hoffmann–La Roche in Canada and the European Union, and by Chugai Pharmaceuticals and Zenyaku Kogyo in Japan.
Lähteet
- ↑ "Why San Diego Has Biotech", Fikes, Bradley J. San Diego Metropolitan, April 1999. Accessed June 20, 2008.
- ↑ Maloney DG, Grillo-López AJ, White CA, et al. (September 1997). "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma". Blood 90 (6): 2188–95. PMID 9310469.
- ↑ Scott SD (1998). "Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma". Cancer Pract 6 (3): 195–7. doi:. PMID 9652253.
- ↑ Harrison's Principles of Internal Medicine, Longo et al. McGraw Hill Medical 2011 page 931
- ↑ "Roche Gets EC Nod for Follicular Lymphoma Maintenance Therapy", October 29, 2010.